Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Merck

144.71
-2.8200-1.91%
Pre-market: 145.250.5400+0.37%05:23 EDT
Volume:7.54M
Turnover:1.09B
Market Cap:357.02B
PE:113.69
High:148.00
Open:147.94
Low:144.10
Close:147.53
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.95
T/O Rate:0.31%
Dividend:3.36
Dividend Rate:2.32%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.51
PE(LYR):19.88

Loading ...

OverviewCompanyNewsFilings

July 2026's Top Stock Selections Estimated Below Fair Market Value

Simply Wall St.
·
Jul 17

Sector Update: Healthcare

MT Newswires Live
·
Jul 17

Merck's HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data, RBC Says

MT Newswires Live
·
Jul 16

Unitedhealth, Merck Share Gains Contribute to Dow's 166-point Jump

Dow Jones
·
Jul 16

Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement

TradingKey
·
Jul 16

Merck (MRK) Rises after FDA Clears First Oral PCSK9 Cholesterol Pill

TIPRANKS
·
Jul 16

Movement Alert｜Merck Rises 3.09% in Regular Trading, Oral PCSK9 Inhibitor Lipfendra Wins FDA Approval

Market Focus
·
Jul 16

Merck Gets US FDA Nod for First-in-its-class Oral Cholesterol Drug

Reuters
·
Jul 16

Merck & Co Inc: List Price (wholesale Acquisition Cost) for Lipfendra Will be $10.50 Per Day, Based on a 30-day Supply

THOMSON REUTERS
·
Jul 16

Merck’s Lipfendra approved by FDA for adults with hypercholesterolemia

TIPRANKS
·
Jul 16

Merck Says FDA Approves Oral PCSK9 Inhibitor Lipfendra for Adults with High LDL-C

Reuters
·
Jul 16

Merck’s Lipfendra® (enlicitide) is the First and Only Once-daily Oral Pcsk9 Inhibitor Approved by the U.S. FDA to Reduce Ldl-c in Adults with Hypercholesterolemia

THOMSON REUTERS
·
Jul 16

Merck: FDA Approves Lipfendra Tablets 20 Mg to Reduce Low-density Lipoprotein Cholesterol in Adults with Hypercholesterolemia

THOMSON REUTERS
·
Jul 16

Citi Sticks to Its Hold Rating for Merck & Company (MRK)

TIPRANKS
·
Jul 16

Merck Buy Rating Reiterated as sac-TMT Data De-Risk Oncology Pipeline; 12-Month Price Target Maintained at $137

TIPRANKS
·
Jul 16

Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled

TradingKey
·
Jul 15

Movement Alert｜Merck Rises 3.06% in Regular Trading, Keytruda Phase 3 Endometrial Cancer Trial Meets Primary Endpoint

Market Focus
·
Jul 15

Merck Shares Rise 3% After Partner Kelun-biotech Reports Positive Keytruda Lung Cancer Study

THOMSON REUTERS
·
Jul 15

Sector Update: Healthcare Stocks Decline Premarket Wednesday

MT Newswires Live
·
Jul 15

Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions

MT Newswires Live
·
Jul 15
More